A 42-year-old woman from Mumbai presents with a 3-week history of progressive swelling and pain in the left lower limb. She denies trauma or recent immobilization. On examination, the left calf is swollen with pitting edema, warmth, and tenderness over the popliteal fossa. Homans sign is positive. She has been taking oral contraceptive pills (containing ethinyl estradiol 35 µg and norethisterone) for the past 18 months for contraception. D-dimer is elevated at 1200 ng/mL (normal <500). Compression ultrasound of the left lower limb shows an echogenic thrombus within the left popliteal vein extending into the superficial femoral vein, with absent compressibility. CT pulmonary angiography is normal. She is started on enoxaparin 1 mg/kg SC twice daily and transitioned to warfarin. On day 5 of anticoagulation, repeat duplex ultrasound shows expansion of the thrombus into the common femoral vein. What is the most likely explanation for the progression of thrombosis despite adequate anticoagulation?

Explanation

## Diagnosis: Thrombotic Progression Due to Persistent Thrombophilic State (OCP Use) ### Clinical Context This patient has deep vein thrombosis (DVT) provoked by oral contraceptive use. Despite initiation of anticoagulation, the thrombus is expanding — a phenomenon called **anticoagulation failure** or **progressive thrombosis despite anticoagulation**. The key clinical error is that the **offending thrombophilic agent (OCP) was not discontinued**. ### Pathophysiology: OCP-Induced Hypercoagulability **Key Point:** Estrogen-containing oral contraceptives increase thrombotic risk through multiple mechanisms: | Mechanism | Effect | |---|---| | **Increased synthesis of clotting factors** | ↑ Factors II, VII, VIII, X, XII, XIII | | **Decreased synthesis of anticoagulants** | ↓ Protein C, protein S, antithrombin | | **Increased platelet reactivity** | ↑ Platelet aggregation and adhesion | | **Endothelial dysfunction** | ↓ Fibrinolytic activity, ↑ PAI-1 | | **Increased inflammation** | ↑ CRP, IL-6, TNF-α | **High-Yield:** The thrombotic risk is dose-dependent (higher estrogen dose = higher risk) and persists as long as the OCP is being used. ### Why Anticoagulation Alone Is Insufficient ```mermaid flowchart TD A[OCP use]:::outcome --> B[Hypercoagulable state]:::outcome B --> C[Thrombus formation]:::outcome C --> D[Start anticoagulation]:::action D --> E{OCP continued?}:::decision E -->|Yes| F[Thrombophilic stimulus persists]:::urgent F --> G[Thrombus propagation despite heparin]:::urgent E -->|No| H[Hypercoagulability resolves]:::action H --> I[Thrombus stabilization and resolution]:::outcome ``` **Clinical Pearl:** Anticoagulation (heparin/warfarin) prevents NEW thrombus formation and promotes fibrinolysis, but it does NOT eliminate the underlying thrombophilic stimulus. If the OCP is continued, the hypercoagulable state persists, and the existing thrombus may continue to propagate. ### Management of OCP-Provoked VTE **Key Point:** The standard approach is: 1. **Immediate discontinuation of OCP** — this is non-negotiable 2. **Initiation of anticoagulation** (LMWH or UFH, then warfarin or DOAC) 3. **Duration of anticoagulation:** 3 months minimum for provoked VTE (OCP-related) 4. **Alternative contraception:** Progestin-only pills, IUD, barrier methods 5. **Thrombophilia screening:** Consider if recurrent VTE or family history ### Why Other Options Are Wrong **Warning:** Common pitfalls in VTE management: - ~~Inadequate enoxaparin dosing~~ — BMI 28 kg/m² is not obese; standard dosing (1 mg/kg) is appropriate - ~~Occult malignancy~~ — No clinical features (weight loss, constitutional symptoms, imaging findings) suggest cancer; malignancy-associated VTE typically presents with extensive thrombosis or PE - ~~Antithrombin deficiency~~ — This is a rare inherited thrombophilia; it would present with recurrent VTE or family history, not acute progressive thrombosis on heparin ### Mnemonic: Causes of Anticoagulation Failure **PERSISTENT THROMBOSIS:** - **P** — Persistent thrombophilic stimulus (OCP, cancer, antiphospholipid syndrome) - **E** — Extensive thrombosis (IVC involvement, iliofemoral) - **R** — Resistance to anticoagulation (antithrombin deficiency, factor V Leiden homozygous) - **S** — Septic thrombophlebitis (infected catheter) - **I** — Inadequate dosing or compliance - **S** — Stent or foreign body - **T** — Thrombophilia (inherited or acquired) - **E** — Embolization requiring intervention - **N** — Neoplasm (occult malignancy) - **T** — Thrombotic storm (catastrophic antiphospholipid syndrome) ### Citation **High-Yield:** Estrogen-containing OCPs increase VTE risk 3–4 fold; this risk is further increased in women with underlying thrombophilia. The absolute incidence is 3–4 per 10,000 woman-years [cite:Harrison 21e Ch 111].